Larvol Delta - ARTEMIDELung04-A-Global-Phase-III-Study-of-Rilvegostomig-or-Pembrolizumab-Monotherapy-for-FirstLine-Treatment-of-PDL1high-Metastatic-Nonsmall-Cell-Lung-Cancer

rilvegostomig (AZD2936) - AstraZeneca

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT06868277

Jul 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next